Detailed Narrative
Q3 & 9M FY26 Performance Overview
Fredun Pharma reported robust financial results for Q3 FY26, with total income growing 57% year-on-year to INR160.92 crores. EBITDA saw a 99% increase to INR26.34 crores, leading to an EBITDA margin of 16%, a 384 basis point expansion. Net profit nearly doubled by 96% to INR10.48 crores, with a net profit margin of 7%. For the nine-month period, total income was INR426 crores (up 48% YoY), EBITDA was INR65.66 crores (up 74% YoY) with a 15% margin, and net profit grew 96% to INR26.98 crores, achieving a 6% net profit margin.
Growth Strategy & Capacity Expansion
The company is undergoing rapid expansion, increasing production capacities at existing plants and adding 37 new partner facilities. This expansion supports the strong traction observed in new brands launched over the past 2-3 years. Management confirmed that current funds are sufficient for the next 12-18 months, with recent fundraise money from Q3 FY26 earmarked for working capital and internal cash flows improving.
Legacy vs. New-Age Business Dynamics
Fredun Pharma's legacy business is projected to grow at 12-18% year-on-year for the next 5-7 years, supported by 1,300-1,400 product registrations in the pipeline. The new-age business, encompassing Gx, pet care, nutritional, mobility, dermaceutics, and cosmetics, is growing at 20-25% year-on-year. For FY26, new-age business is targeted to contribute approximately INR60 crores from Gx, INR42 crores from pet care, and INR26 crores from nutritional segments. The company aims for new-age business to constitute 51% of total revenue by 2029-2030.
Profitability & Margin Outlook
Management considers a PAT margin of 5-6% sustainable given the current growth trajectory. However, a 'sudden growth in profits' is anticipated in the next 2-3 years (or 6-7 quarters), driven by operational efficiencies from high-margin new-age businesses, which boast gross margins of 50-70%. The increase in finance costs in Q3 FY26 is attributed to working capital needs and new machinery loans, but these costs are expected to decline over the next 2-3 quarters as fundraise money is utilized.
Manufacturing Strategy for New-Age Business
For its new-age products, Fredun Pharma is adopting an asset-light manufacturing strategy. The company does not intend to build dedicated plants for all new product types, such as wheelchairs. Instead, it plans to leverage third-party manufacturers' cost efficiencies. This approach means that within 4-5 years, a growing proportion of products will be manufactured externally, allowing the company to penetrate markets more effectively.
Mobility Segment Expansion & Penetration
The mobility segment, which includes over 800 products under brands like 'Braceon' (ortho), 'DGon' (BP meters), and 'Nebon' (nebulizers), is growing at 25-30% year-on-year. The company is actively expanding its distribution, adding 30-40 retail outlets weekly. It plans to add 4-5 more states in the coming year, aiming to cover approximately 60% of India. Operational leverage from states like Maharashtra, where products are widely available, is expected to kick in within 9 months, with overall leverage from new brands anticipated in 5-7 quarters.